Neovii Pharmaceuticals AG
About Neovii Pharmaceuticals AGNeovii is an independent, dynamic and rapidly-growing global biopharmaceutical company with patient-focused mission to develop and market novel life-transforming therapies. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
CEO: Alexandre Sudarskis
CCO: Jürgen Pohle
CFO: Bernhard Saalfrank
Please click here for Neovii job opportunities.
6 articles about Neovii Pharmaceuticals AG
Neovii Pharmaceuticals AG and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd have entered into an exclusive agreement, under which Neovii has granted Fosun Pharma Industry an exclusive license to develop and commercialize Neovii's Grafalon® in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.
Neovii, the Swiss-based biopharmaceutical company and a member of Israeli-based Neopharm Group, has signed a research and license agreement with Tel Aviv University's (TAU) RAMOT, its technology transfer company, to work in collaboration with a team led by Professor Jonathan Gershoni of the School of Molecular Cell Biology an
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
Neovii Announces Publication in Journal of Clinical Oncology Demonstrating Grafalon Reduces Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation
The randomized, double blind, phase III, trial investigates the utility of Grafalon in reducing moderate to severe chronic graft-versus-host-disease.
Neovii Pharma: Long-Term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis In Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support The Use Of Grafalon (Anti-Human-T-Lymphocyte Immunoglobulin) As Standard Thera